CSPC Pharmaceutical and AstraZeneca have entered into a 51:49 joint venture agreement to develop a next-generation biologics manufacturing facility in Shijiazhuang, China.
The partnership is designed to combine complementary strengths:
🔹 CSPC Pharmaceutical: AI-driven GMP systems, pharmaceutical manufacturing expertise, and facility construction & operations
🔹 AstraZeneca: Global quality standards, manufacturing expertise, and international supply chain capabilities
The new facility will initially focus on the production of biologics drug substances for global markets, supporting the partners’ broader ambitions in advanced pharmaceutical manufacturing and international supply chains.
💡 While the investment value has not been disclosed, the project represents another significant step toward strengthening China’s high-end biopharmaceutical manufacturing ecosystem and expanding global production capabilities.
The collaboration also reflects a broader industry trend—pharmaceutical companies are increasingly combining technology, AI-enabled manufacturing, quality systems and global supply chains to build more resilient production networks.
📈 Strategic partnerships like this could play a key role in shaping the next generation of global biologics manufacturing.
#Pharmaceuticals #Biologics #Biomanufacturing #AstraZeneca #CSPCPharmaceutical #China #Manufacturing #LifeSciences #PharmaIndustry #Investment #SupplyChain #GMP #AI #Healthcare
